For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE), according to a study scheduled for presentation at the annual meeting of the American Society of Hematology, to be held from Dec. 7 to 10 in San Diego.
This article was originally published on MedicalXpress.com